Tuesday, July 30, 2019 11:32:28 PM
Leap Therapeutics , Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Leap Therapeutics , Inc. ( LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. (Source: https://finance.yahoo.com/news/leap-ther...)
SHORT INTEREST
2.1M 07/15/19
P/E Current
-0.95
P/E Ratio (with extraordinary items)
-1.34
Average Recommendation: BUY
Average Target Price: 9.00
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent LPTX News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 09:01:55 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:27 AM
- Leap Therapeutics Announces $40 Million Private Placement • PR Newswire (US) • 04/11/2024 12:30:00 PM
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/18/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:36:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:36:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:35:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:35:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:35:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:34:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:34:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:34:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 01:41:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 01:39:35 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/26/2024 10:21:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:28:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:10:22 PM
- Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium • PR Newswire (US) • 01/16/2024 10:05:00 PM
- Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/03/2024 12:00:00 PM
- Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients • PR Newswire (US) • 01/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:02:47 PM
- Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium • PR Newswire (US) • 12/11/2023 09:05:00 PM
- Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference • PR Newswire (US) • 11/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:10:40 PM
- Leap Therapeutics Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM